These phenotypes mirror the metabolic profiles described for MYC-driven SCLC and are marked by high asparagine, arginine, and polyamine flux, as well as hyperactive mTOR signaling—all contributing to relentless proliferative and metastatic gain. This evidence concerns the gene MYC and small cell lung carcinoma.